Saniona AB

Acadia Pharmaceuticals CEO Catherine Owen Adams is focused on executing near-term growth and building out a pipeline to continue the momentum the company has built in the past year. Owen Adams joined

Who: Acadia and Saniona What: The US biotech has licensed the Danish firm’s SAN711, a first-in-class highly selective GABAA-α3 positive allosteric modulator. Acadia is planning to initiate a Phase

The recent approval of Eli Lilly and Company ’s Zepbound (tirzepatide) for obesity means two highly effective incretin drugs are now available for obesity. Lilly believes it can supply Zepbound in la

The success of incretin mimetics – most notably Novo Nordisk Pharma AG ’s Wegovy – in obesity is so extraordinary that large numbers of similarly acting agents are being pushed through clinical trial